NEW! Investment Companies Centre

TechMARK movers: Ardana falls on trial result

Related Companies

Related Indices

Related Sectors

News for Spread Betters

PreviousPrevious
NextNext

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here. Advertisement

Date: Tuesday 13 May 2008

LONDON (ShareCast) - Drug developer Ardana fell back on a disappointing trial result for its new testosterone cream, which is now unlikely to meet the expected target for patients to get approval from the US Food and Drug Administration.

"It would be prudent to assume that a further study may be required for regulatory approval of Testosterone Cream," Ardana said.

The company added that it continues to hold discussions with potential bidders and also over licensing opportunities.

Inkjet printing specialist Xaar said gross margins across the product range are stable, operating costs continue to be controlled successfully and trading for the company as a whole for 2008 is in line with expectations.

FTSE TechMARK - Fallers
Ardana (ARA) 13.00p -17.46%
NXT (NTX) 20.75p -7.78%
Skyepharma (SKP) 9.33p -6.70%
Phytopharm (PYM) 21.00p -5.62%
Optos (OPTS) 176.00p -4.61%
Detica Group (DCA) 297.00p -3.88%
Wolfson Microelectronics (WLF) 132.50p -3.81%
Parity Group (PTY) 31.00p -3.12%
Oxford Biomedica (OXB) 23.25p -3.12%
Antisoma (ASM) 27.00p -2.70%

FTSE TechMARK - Risers
Vectura Group (VEC) 53.50p +5.94%
KCOM Group (KCOM) 55.75p +5.69%
Pace Micro (PIC) 86.00p +3.61%
Vtech (VTH) 307.50p +3.36%
Biocompatibles International (BII) 151.75p +3.06%
Renovo Group (RNVO) 34.00p +3.03%
Intec Telecom (ITL) 54.25p +2.84%
Imagination Technologies (IMG) 73.75p +2.43%
Xaar (XAR) 185.50p +1.92%
GB Group (GBG) 30.75p +1.65%

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).